Securities code: 002589 securities abbreviation: Realcan Pharmaceutical Group Co.Ltd(002589) Announcement No.: 2022-014 Realcan Pharmaceutical Group Co.Ltd(002589)
Announcement of the resolutions of the 18th meeting of the 4th board of supervisors
The company and all members of the board of supervisors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements and major omissions.
Realcan Pharmaceutical Group Co.Ltd(002589) (hereinafter referred to as “the company”) the notice of the 18th meeting of the fourth session of the board of supervisors was issued in writing on February 11, 2022 and held by on-site voting in the conference room on the fourth floor of the company, 326 Airport Road, Yantai on the morning of February 17, 2022. The meeting was presided over by Wu Liyan, chairman of the board of supervisors. Three supervisors should attend the meeting and three actually attended the meeting. The meeting was held in accordance with the company law of the people’s Republic of China and the articles of association. After deliberation by the supervisors present at the meeting, the following resolutions were reached: first, the proposal on the acquisition of 38.39992% equity and related party transactions of Tianjin guohuida Health Technology Co., Ltd. was deliberated and adopted.
The company plans to use its own funds to acquire 38.39992% equity of Tianjin guohuida Health Technology Co., Ltd. (hereinafter referred to as the “target company”) from Yantai huishuo enterprise management partnership (limited partnership), Taking the asset appraisal report on the value of all shareholders’ equity of Tianjin guohuida Health Technology Co., Ltd. (Beiya Shi Ping Bao Zi [2022] No. 01-042) involved in the proposed equity acquisition issued by Beiya Shi Asset Appraisal Office (special general partnership) on January 28, 2022 as the transaction basis and agreed by both parties through consultation, The audited amount of the underlying equity was RMB 148803.08, accounting for 23008% of the previous year’s net equity.
The proposal was adopted by 3 votes in favor, 0 against and 0 abstention.
It is hereby announced.
Realcan Pharmaceutical Group Co.Ltd(002589) board of supervisors
February 18, 2022
